ACAD
NASDAQ · Biotechnology
Acadia Pharmaceuticals Inc
$20.96
-0.03 (-0.14%)
Financial Highlights (FY 2026)
Revenue
978.99M
Net Income
231.46M
Gross Margin
91.5%
Profit Margin
23.6%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 91.5% | 38.8% | 38.8% | 38.8% |
| Operating Margin | 24.1% | 17.6% | 15.6% | 17.1% |
| Profit Margin | 23.6% | 18.5% | 16.3% | 14.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 978.99M | 997.69M | 1.03B | 1.09B |
| Gross Profit | 895.39M | 387.27M | 398.68M | 424.99M |
| Operating Income | 235.94M | 175.96M | 160.64M | 187.08M |
| Net Income | 231.46M | 184.03M | 167.73M | 158.84M |
| Gross Margin | 91.5% | 38.8% | 38.8% | 38.8% |
| Operating Margin | 24.1% | 17.6% | 15.6% | 17.1% |
| Profit Margin | 23.6% | 18.5% | 16.3% | 14.5% |
| Rev Growth | — | +23.8% | +10.0% | -1.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 1.43B | 1.70B | 1.80B |
| Total Equity | — | 1.96B | 1.87B | 1.74B |
| D/E Ratio | — | 0.73 | 0.91 | 1.03 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 238.71M | 233.49M | 233.13M | 238.00M |
| Free Cash Flow | — | 197.34M | 189.95M | 154.06M |